Loading
A phase 1/2 trial of HS-10375 in non-small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) is a phase 1/2 interventional study registered as NCT05435248 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 354 participants planned, started 2022-03-02 and due to reach its primary completion in 2025-03-31. Interventions recorded: HS-10375.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Hansoh Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Hansoh Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/